111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
病例报告：一例使用依夫格替莫德成功治疗的兰伯特 - 埃顿肌无力综合征患者
Authors Han L, Shen J, Wei J, Zhang Y
Received 31 July 2025
Accepted for publication 17 November 2025
Published 27 November 2025 Volume 2025:18 Pages 1507—1511
DOI https://doi.org/10.2147/IMCRJ.S555977
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Vinay Kumar
Lizhu Han,1,2 Jili Shen,3 Jie Wei,3 Yue Zhang2
1Department of Neurology, Anhui No.2 Provincial People’s Hospital, Hefei, Anhui, People’s Republic of China; 2Department of Neurology, National Center for Neurological Disorders, Huashan Rare Disease Centre, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Department of Neurology, 905th Hospital of PLA Navy, Shanghai, People’s Republic of China
Correspondence: Yue Zhang, Email zygadene@163.com Jie Wei, Email 13501717467@163.com
Background: Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder which is frequently associated with tumors. Those patients generate pathogenic antibodies such as voltage-gated calcium channel (VGCC) antibodies. Existing studies have established the efficacy of efgartigimod in MG. This article reports the effect of efgartigimod following its administration to a patient with LEMS.
Case Presentation: A 73-year-old male was diagnosed with small cell lung cancer two years ago. Gradually he developed difficulties in speaking, eating, and lifting his head, along with limb weakness. The neuroelectrophysiological examination findings were consistent with LEMS. Laboratory tests detected VGCC antibodies and SOX-1 antibodies in the serum. The patient’s symptoms continued to worsen after one week of corticosteroids use. Consequently, efgartigimod at a dose of 10 mg/kg was added once a week. After three weeks of treatment, the patient’s clinical manifestations had improved significantly. Laboratory tests revealed a decrease in serum VGCC antibody and IgG levels.
Conclusion: This is the first report on the use of efgartigimod in LEMS. The patient demonstrated substantial clinical improvement following treatment. Nevertheless, more clinical studies are required to verify whether efgartigimod offers a novel treatment approach for patients with LEMS.
Keywords: LEMS, Efgartigimod, VGCC, SOX-1
1Department of Neurology, Anhui No.2 Provincial People’s Hospital, Hefei, Anhui, People’s Republic of China; 2Department of Neurology, National Center for Neurological Disorders, Huashan Rare Disease Centre, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 3Department of Neurology, 905th Hospital of PLA Navy, Shanghai, People’s Republic of China
Correspondence: Yue Zhang, Email zygadene@163.com Jie Wei, Email 13501717467@163.com
Background: Lambert-Eaton myasthenic syndrome (LEMS) is a neuromuscular junction disorder which is frequently associated with tumors. Those patients generate pathogenic antibodies such as voltage-gated calcium channel (VGCC) antibodies. Existing studies have established the efficacy of efgartigimod in MG. This article reports the effect of efgartigimod following its administration to a patient with LEMS.
Case Presentation: A 73-year-old male was diagnosed with small cell lung cancer two years ago. Gradually he developed difficulties in speaking, eating, and lifting his head, along with limb weakness. The neuroelectrophysiological examination findings were consistent with LEMS. Laboratory tests detected VGCC antibodies and SOX-1 antibodies in the serum. The patient’s symptoms continued to worsen after one week of corticosteroids use. Consequently, efgartigimod at a dose of 10 mg/kg was added once a week. After three weeks of treatment, the patient’s clinical manifestations had improved significantly. Laboratory tests revealed a decrease in serum VGCC antibody and IgG levels.
Conclusion: This is the first report on the use of efgartigimod in LEMS. The patient demonstrated substantial clinical improvement following treatment. Nevertheless, more clinical studies are required to verify whether efgartigimod offers a novel treatment approach for patients with LEMS.
Keywords: LEMS, Efgartigimod, VGCC, SOX-1